What AIM ImmunoTech Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 6 | 6 |
| Sells | 0 | 0 |
| Total trades | 6 | 9 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 125,825 | 442,625 |
| Disposed | 0 | 0 |
| Net activity | +125,825 | +442,625 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Equels Thomas K. | CEO & President | Oct 23 | Open-market buy · P | +31,675 | $0.16 | +$5.07K | 189,747 |
| Equels Thomas K. | CEO & President | Oct 22 | Open-market buy · P | +31,250 | $0.16 | +$5.09K | 158,072 |
| Equels Thomas K. | CEO & President | Sep 17 | Open-market buy · P | +24,000 | $0.21 | +$4.99K | 126,822 |
| Equels Thomas K. | CEO & President | Sep 16 | Open-market buy · P | +11,000 | $0.21 | +$2.31K | 102,822 |
| Equels Thomas K. | CEO & President | Sep 15 | Open-market buy · P | +22,000 | $0.22 | +$4.86K | 91,822 |
| Equels Thomas K. | CEO & President | Sep 14 | Open-market buy · P | +5,900 | $0.22 | +$1.29K | 69,822 |
| Chemerow David | Director | Mar 12 | Derivative Conversion · C | +25,000 | — | — | 28,441 |
| Equels Thomas K. | CEO & President | Mar 12 | Derivative Conversion · C | +25,000 | — | — | 63,922 |
| Chemerow David | Director | Feb 05 | Grant / award · A | +2,800 | $1.23 | +$3.44K | 3,441 |
| Equels Thomas K. | CEO & President | Jun 13 | Open-market buy · P | +107 | $7.70 | +$824 | 38,885 |
| Equels Thomas K. | CEO & President | Jun 12 | Open-market buy · P | +103 | $8.70 | +$896 | 38,675 |
| Kellner Ted D | Director | Apr 11 | Open-market buy · P | +1,968,504 | $0.03 | +$50K | 1,969,504 |
| Equels Thomas K. | CEO & President | Apr 11 | Open-market buy · P | +1,968,504 | $0.03 | +$50K | 3,867,533 |
| Mitchell William M | Director | Apr 11 | Open-market buy · P | +196,851 | $0.03 | +$5K | 521,723 |
| Rodino Peter W. Iii | COO, Secretary, Gen. Counsel | Apr 04 | Open-market buy · P | +500 | $0.09 | +$43.5 | 401,762 |
| Equels Thomas K. | CEO & President | Apr 04 | Open-market buy · P | +41,000 | $0.06 | +$2.58K | 1,899,029 |
| Chemerow David | Director | Mar 14 | Grant / award · A | +44,899 | $0.12 | +$5.21K | 64,189 |
| Mitchell William M | Director | Mar 14 | Grant / award · A | +44,899 | $0.12 | +$5.21K | 324,872 |
| Bryan Nancy | Director | Mar 14 | Grant / award · A | +44,899 | $0.12 | +$5.21K | 291,882 |
| Equels Thomas K. | CEO & President | Mar 05 | Open-market buy · P | +50,000 | $0.13 | +$6.73K | 1,858,029 |
Loading...
